Hyperuricemia and chronic kidney disease: to treat or not to treat

Area of Science:

• Nephrology
• Biochemistry
• Genetics

Background:

• Hyperuricemia affects up to 50% of patients with chronic kidney disease (CKD), often preceding or accompanying kidney damage.
• Both soluble and crystalline uric acid have been implicated in experimental models, causing kidney ischemia, fibrosis, and inflammation.
• Previous Mendelian randomization studies and clinical trials have yielded inconsistent results regarding the causal link between uric acid and CKD.

Purpose of the Study:

• To investigate the complex relationship between hyperuricemia and chronic kidney disease (CKD).
• To reconcile conflicting findings from genetic and clinical studies on uric acid's role in kidney injury.
• To propose mechanisms and future directions for understanding and treating uric acid-mediated kidney damage.

Main Methods:

• Review of experimental studies on hyperuricemic models.
• Analysis of Mendelian randomization studies and clinical trial data.
• Exploration of potential mechanisms including crystalline uric acid, intracellular uric acid, and xanthine oxidase activity.

Main Results:

• Experimental data suggest uric acid can cause kidney damage.
• Genetic and clinical studies have shown variable or inconclusive results on causality.
• Potential explanations for discrepancies include the form of uric acid (soluble vs. crystalline) and intracellular effects.

Conclusions:

• The relationship between uric acid and CKD is complex and requires further investigation.
• Crystalline uric acid, intracellular uric acid, and xanthine oxidase activity may play crucial roles in kidney injury.
• Future clinical trials and treatment algorithms are proposed to address hyperuricemia in CKD patients.